Clinical trials: Hepatitis B, completed
Hepatitis B
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants
To assess the efficacy, immune response and safety of 2 doses of HRV vaccine (at different concentrations) in healthy infants aged approximately 3 months previously uninfected with human rotavirus.
- Trial name
- NCT00429481
- Testing
- Rotarix
- Volunteers
- 2,464 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B Infection
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have…
- Trial name
- NCT05355467
- Testing
- Tenofovir disoproxil fumarate, Historical Data
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Mylan (Taiwan) Ltd
Hepatitis
Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents
The purpose of this study is to determine the immune response to an additional (booster) dose of hepatitis B vaccine 5-14 years after a three dose series was given
- Trial name
- NCT00141999
- Testing
- hepatitis B vaccine
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
To demonstrate the dose response of entecavir in Japanese patients as measured by HBV DNA levels by PCR (log10 copies/mL) at Week 22
- Trial name
- NCT01022801
- Testing
- Entecavir
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Infant, Healthy
Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®
The purpose of the study is to provide data on the safety and immunogenicity of Pediacel® to allow its use as a fourth dose administered to 11-18 months old toddlers at the same time as Prevenar®.
- Trial name
- NCT00355654
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, DT3aP-HBs-IPV
- Where
- 84 sites in Germany
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Human Immunodeficiency Virus-Infection
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.
- Trial name
- NCT01153269
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 8 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Abbott
Chronic Hepatitis B
An Study of Efficacy and Safety of Clevudine
Randomized, double blind parallel group, positive control, multi-center trial. Patients will be randomized at 1:1 ratio in group A or group B
- Trial name
- NCT01192854
- Testing
- Clevudine, Adefovir
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Hepatitis B, Poliomyelitis
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course
The study will compare the immunogenicity and the reactogenicity of INFANRIX™ HEXA and HEXAVAC™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.
- Conditions
- Hepatitis B, Poliomyelitis, Diphtheria, Acellular Pertussis
- Trial name
- NCT01457547
- Testing
- DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA), DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
- Where
- 9 sites in Finland, Italy and 1 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HBV Infection
The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication
The purpose of this study is to determine whether the general anesthesia immunosuppressive could effect hepatitis B Virus replication
- Trial name
- HBV (NCT02038088)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Lu KZ
Chronic Hepatitis B Virus Infection
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of…
- Trial name
- NCT07515209
- Testing
- HH-006, 0.9% normal saline
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Huahui Health
HIV and Hepatitis B Coinfection
TAF for HIV-HBV With Renal Dysfunction
The investigators aim at describing changes in renal glomerular and tubular function with after the switch from TDF to TAF in HIV/HBV-coinfected patients with mild to moderate renal dysfunction and to assess the virological…
- Trial name
- NCT03115736
- Testing
- Tenofovir Alafenamide
- Where
- 8 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Chronic Hepatitis B-related Liver Fibrosis
A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis
This trial employs a single-arm, open-label, multicenter clinical trial design. All study participants who meet the inclusion/exclusion criteria will receive Hydronidone treatment for 4 weeks.
- Trial name
- NCT07417553
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatitis B
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe in patients at least 40 years of age who have progressive loss of kidney function with more advanced stage 3 (GFR ≤…
- Trial name
- NCT00426712
- Testing
- 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)
The purpose of this trial is to determine if there is an improvement in the immune response of older adults over 50 years of age using a modified process hepatitis B vaccine and a currently licensed hepatitis B vaccine…
- Trial name
- NCT00440531
- Testing
- Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), Comparator: Modified Process Hepatitis B Vaccine (Experimental), Comparator: ENGERIX-B™ (currently licensed product)
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, HIV Infection
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)
HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic and severe liver disease, with a major risk of cirrhosis and liver cancer.
- Trial name
- B-BOOST (NCT00670839)
- Testing
- GenHevac-B
- Where
- France
- Volunteers
- 178 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis B
Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant hepatitis B vaccine (Hansenula polymorpha, 10μg), with an open-labelled design in adults and randomized, double-blinded, and positive…
- Trial name
- NCT04075201
- Testing
- One dose of investigational vaccine, One dose of control vaccine, Three doses of investigational vaccine
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Substudy C: The purpose of this substudy is to determine whether Lambda combined with Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic HCV infection
- Trial name
- D-LITE (NCT01795911)
- Testing
- Pegylated Interferon Lambda, Ribasphere, Daclatasvir
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Hepatocellular Carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 39 subjects with Hepatitis B virus (HBV) related HCC after liver…
- Trial name
- NCT02686372
- Testing
- TCR-T, No intervention and TCR-T (at crossover)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Lion TCR Pte. Ltd.
Chronic Hepatitis B
Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg once daily (QD) taken together versus tenofovir DF 300 mg once…
- Trial name
- NCT00804622
- Testing
- telbivudine, tenofovir disproxil fumarate, telbivudine plus tenofovir disproxil fumarate
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.